BISOPROLOL FUMARATE Drug Interactions
Also known as: Bisoprolol Fumarate
Bisoprolol fumarate is a beta-blocker medication used to treat high blood pressure (hypertension). It works by relaxing blood vessels and slowing the heart rate, which helps the heart pump blood more easily throughout the body. This medication can be used alone or with other medicines to manage blood pressure.BISOPROLOL FUMARATE has 7 documented drug interactions in our database, including 0 contraindicated, 0 major, 0 moderate, and 7 minor interactions.
0
Contraindicated
0
Major
0
Moderate
7
Minor
The interaction between bisoprolol and sertraline is generally considered minor. While both drugs can independently cause bradycardia, sertraline has minimal impact on the metabolism of bisoprolol, which is primarily renally cleared.
Mechanism
Bisoprolol is primarily eliminated via renal excretion, with minimal involvement of CYP2D6. Sertraline is a weak inhibitor of CYP2D6, and therefore, it is not expected to significantly alter bisoprolol plasma concentrations.
Clinical Management
No specific dose adjustments are typically required for bisoprolol or sertraline when co-administered. However, clinicians should monitor patients for additive pharmacodynamic effects such as bradycardia, especially in sensitive individuals. Routine monitoring of heart rate and blood pressure is advisable.
The interaction between bisoprolol and fluoxetine is generally considered minor. While fluoxetine is a potent CYP2D6 inhibitor, bisoprolol is primarily renally cleared, minimizing the pharmacokinetic interaction risk. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are possible.
Mechanism
Fluoxetine is a potent inhibitor of CYP2D6. However, bisoprolol is primarily eliminated renally with minimal CYP2D6 metabolism, thus significant pharmacokinetic interaction via this pathway is unlikely. Both drugs can exert bradycardic effects, leading to potential additive pharmacodynamic effects.
Clinical Management
Generally, no specific dose adjustments are required for bisoprolol when co-administered with fluoxetine due to the minimal pharmacokinetic interaction. However, clinicians should monitor patients for signs of excessive bradycardia or hypotension, especially when initiating or significantly changing fluoxetine dosage. If such symptoms occur, consider reducing the bisoprolol dose.
Bisoprolol and citalopram are generally considered safe to use together. While both drugs can independently affect heart rate, the risk of a significant interaction leading to severe bradycardia or other adverse cardiac events is low, especially given bisoprolol's renal clearance.
Mechanism
Citalopram is a weak inhibitor of CYP2D6, but bisoprolol is primarily eliminated renally with minimal CYP2D6 involvement, thus pharmacokinetic interaction is unlikely. A theoretical additive pharmacodynamic effect on heart rate is possible, but not clinically significant for this combination.
Clinical Management
No specific dose adjustments are typically required for this combination. Monitor patients for expected therapeutic effects and any signs of excessive bradycardia or hypotension, especially at treatment initiation or dose changes, as with any beta-blocker therapy.
Fluoxetine is a potent CYP2D6 inhibitor, but bisoprolol is primarily cleared renally with minimal CYP2D6 involvement. Therefore, a clinically significant pharmacokinetic interaction via CYP2D6 inhibition is unlikely. Both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible, though less likely to be significant.
Mechanism
Fluoxetine inhibits CYP2D6, but bisoprolol metabolism is not significantly dependent on CYP2D6. Both drugs can exert bradycardic effects, leading to a theoretical additive pharmacodynamic effect.
Clinical Management
Routine monitoring for expected therapeutic effects and adverse reactions of both medications is recommended. Specific dose adjustments due to this interaction are generally not necessary. Patients should be advised to report any symptoms of excessive bradycardia or hypotension.
The interaction between bisoprolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal impact on the metabolism of bisoprolol, which is primarily renally cleared.
Mechanism
Bisoprolol is primarily eliminated renally with minimal CYP2D6 involvement. Escitalopram has minimal CYP2D6 inhibitory activity, therefore, it is unlikely to significantly alter bisoprolol plasma concentrations. An additive pharmacodynamic effect leading to bradycardia is theoretically possible but rarely clinically significant.
Clinical Management
Generally, no specific dose adjustments are required. Monitor patients for signs of excessive bradycardia or hypotension, especially when initiating or adjusting doses of either medication. If significant bradycardia occurs, consider dose reduction of one or both agents or alternative therapies.
The interaction between bisoprolol and paroxetine is generally considered minor. While paroxetine is a potent CYP2D6 inhibitor, bisoprolol is primarily renally cleared and minimally metabolized by CYP2D6, reducing the likelihood of a significant pharmacokinetic interaction. However, both drugs can independently cause bradycardia, so additive effects on heart rate are theoretically possible.
Mechanism
Paroxetine is a potent inhibitor of CYP2D6. However, bisoprolol is predominantly eliminated by renal excretion with minimal hepatic metabolism, and CYP2D6 plays a negligible role in its clearance. Therefore, paroxetine's CYP2D6 inhibition is unlikely to significantly alter bisoprolol plasma levels. Both drugs can have bradycardic effects.
Clinical Management
Close monitoring for excessive bradycardia or hypotension is generally not required unless the patient has pre-existing cardiac conditions that predispose them to these effects. No routine dose adjustment for either medication is typically necessary. If symptoms of bradycardia occur, evaluate for other causes or consider dose adjustment if deemed clinically appropriate.
Bisoprolol is primarily renally cleared and not significantly metabolized by CYP450 enzymes inhibited by fluvoxamine (CYP1A2, CYP2C19). Therefore, a significant pharmacokinetic interaction is unlikely. However, both drugs can independently cause bradycardia, so an additive pharmacodynamic effect is theoretically possible.
Mechanism
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19. Bisoprolol is primarily eliminated renally with minimal CYP450 metabolism, thus fluvoxamine's inhibitory effects are not expected to significantly alter bisoprolol plasma levels. An additive pharmacodynamic effect on heart rate is possible.
Clinical Management
Generally, no specific dose adjustments are required for bisoprolol when co-administered with fluvoxamine due to the lack of significant pharmacokinetic interaction. Monitor patients for signs of excessive bradycardia or hypotension, especially if they are sensitive to either medication, though this is considered a low risk.
For complete prescribing information:
View full BISOPROLOL FUMARATE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.